Welcome to our dedicated page for Humana news (Ticker: HUM), a resource for investors and traders seeking the latest updates and insights on Humana stock.
Humana Inc. reports news around its U.S. healthcare business, combining Humana insurance services with CenterWell healthcare services. Company updates commonly address Medicare Advantage and other health plan membership, Insurance segment benefit ratios, GAAP and adjusted earnings, full-year guidance, and capital returns through quarterly dividends.
News also covers CenterWell's senior-focused primary care, home health, pharmacy, hospice and retail pharmacy activities; prescription access and home delivery partnerships; healthcare research tied to medication adherence and chronic disease care; palliative care arrangements; health data interoperability; and board refreshment or other governance actions.
Humana (NYSE:HUM) has gone live with b.well Connected Health to centralize member health data and support interoperability commitments on April 9, 2026. Humana will leverage b.well’s national network to access normalized longitudinal records across providers, plans, labs, wearables and digital apps in real time.
This collaboration supports Humana’s CMS Health Technology Ecosystem pledge, aims to reduce administrative waste, enable point-of-claims data access, and participates in an HHS interoperability demonstration.
Humana (NYSE:HUM) and CPESN® USA launched a Pharmacist Quality Rewards program in Ohio on April 8, 2026 to improve care for members with hypertension and diabetes. The value-based program financially rewards community pharmacists for closing care gaps tied to NCQA HEDIS measures including CBP, GSD (A1c <8%), and BPD.
Participating CPESN pharmacies receive member lists and point-of-care tools to identify gaps, offer same-day testing, notify prescribers of out-of-range results, and encourage follow-up care.
Humana (NYSE: HUM) released its corrected 2025 Impact Report on April 6, 2026, detailing progress on simpler, more affordable, and connected care.
Key metrics: nearly 8 million Medicare Advantage/PDP members supported, 1.48 million Medicaid members served, 24.3% fewer inpatient admissions in value‑based care, and a 38% vehicle fleet footprint reduction.
Humana (NYSE:HUM) released its 2025 Impact Report outlining progress on affordability, access, community programs and environmental stewardship. Key metrics include support for nearly 8 million Medicare Advantage and prescription drug plan members, 1.48 million Medicaid members, 24.3% fewer inpatient admissions and a 38% vehicle fleet footprint reduction.
The report highlights community outreach (1.6 million lives via Humana Community Day), workforce belonging at 78%, and a 93% waste diversion rate across sites.
Humana (NYSE: HUM) will release its first-quarter 2026 (1Q26) financial results and prepared management remarks at 6:00 a.m. ET on April 29, 2026. A live Q&A session will follow at 8:00 a.m. ET the same day to discuss results and 2026 earnings guidance.
A webcast and archived presentation will be available on Humana’s Investor Relations page, and the news release will include reconciliations of non-GAAP to GAAP measures.
Humana (NYSE:HUM) and Yale researchers report a sharp rise in continuous glucose monitor (CGM) use among Medicare Advantage members with type 2 diabetes from January 2021 to December 2023. The share of insulin-using members on CGMs grew from under 2% to about 16.7% (roughly 1 in 6).
The study found CGM users often had more complex health profiles, endocrinology visits increased CGM use (>4x likelihood), and the oldest and least-engaged patients were less likely to use CGMs. Humana notes most Medicare Advantage members will have no out-of-pocket cost for CGMs in 2026.
Humana (NYSE: HUM) completed a public offering of $1.0 billion aggregate principal amount of fixed-to-fixed rate junior subordinated notes due 2056 at an annual rate of 6.625%. The company expects net proceeds of approximately $986 million after underwriting discounts and estimated offering expenses.
The company intends to use net proceeds for general corporate purposes, which may include repaying existing indebtedness, including borrowings under its commercial paper program.
Humana (NYSE: HUM) issued $1.0 billion of 6.625% fixed-rate junior subordinated notes due 2056, receiving an AM Best long-term issue credit rating of bbb- with a stable outlook.
AM Best expects the issuance to raise AM Best–measured financial leverage to about 41.8%, modestly above Humana's long-term 40% target, and noted solid but reduced liquidity and EBIT interest coverage of 4–8x.
Humana (NYSE: HUM) priced a public offering of $1.0 billion aggregate principal of fixed-to-fixed rate junior subordinated notes due 2056, at 100.000% of principal. The offering is expected to close on March 9, 2026 and net proceeds are estimated at approximately $986 million.
The company intends to use net proceeds for general corporate purposes, which may include repayment of existing indebtedness and commercial paper borrowings. Joint book-running managers include Goldman Sachs, J.P. Morgan, Mizuho, Truist and Wells Fargo.
Humana (NYSE:HUM) announced on March 3, 2026 new value-based cardiology partnerships to expand cardiac care for eligible Medicare Advantage members.
New agreements with Karoo Health, US Heart and Vascular, Chamber Cardio and expanded Novocardia services add remote monitoring, 24/7 hotlines, integrated care teams and localized value-based care across multiple states.